Publications

Project Publications

Brosseau JP, Sathe AA, Wang Y, Nguyen T, Glass DA 2nXing C, Le LQ. Human cutaneous neurofibroma matrisome revealby single-cell RNA sequencing. Acta Neuropathol Commun. 2021 J7;9(1):11. doi: 10.1186/s40478-020-01103-4. PMCID: PMC7792184.

Mo J, Anastasaki C, Chen Z, Shipman T, Papke J, Yin Gutmann DH, Le LQ. Humanized neurofibroma model from inducpluripotent stem cells delineates tumor pathogenesis adevelopmental origins. J Clin Invest. 2021 Jan 4;131(1):e13980doi: 10.1172/JCI139807. PMCID: PMC7773354.

Pikman Y, Stieglitz E. Targeting the Ras pathway in pediatric hematologic malignancies. Curr Opin Pediatr. 2021 Feb 1;33(1):49-58. doi: 10.1097/MOP.0000000000000981. Epub 2020 Dec 29. PMCID: PMC7880552 (available on 2022-02-01).

Wang Z, Sun D, Chen YJ, Xie X, Shi Y, Tabar V, BrennCW, Bale TA, Jayewickreme CD, Laks DR, Alcantara Llaguno Parada LF. Cell Lineage-Based Stratification for GlioblastomCancer Cell. 2020 Sep 14;38(3):366-379.e8. doi: 10.1016/j.cce2020.06.003. Epub 2020 Jul 9. PMCID: PMC7494533 (available 2021-09-14)

Mund JA, Park S, Smith AE, He Y, Jiang L, Hawley Roberson MJ, Mitchell DK, Abu-Sultanah M, Yuan J, Bessler WSandusky G, Chen S, Zhang C, Rhodes SD, Clapp DW. Genetdisruption of the small GTPase RAC1 prevents plexifoneurofibroma formation in mice with neurofibromatosis type 17.Biol Chem. 2020 Jul 17;295(29):9948-9958.doi: 10.1074/jbc.RA1010981. Epub 2020 May 29. PMCID: PMC7380178 (available 2021-07-17).

Armstrong AE, Rhodes SD, Smith A, Chen S, Bessler Ferguson MJ, Jiang L, Li X, Yuan J, Yang X, Yang FC, RobertsKA, Ingram DA, Blakeley JO, Clapp DW. Early administration imatinib mesylate reduces plexiform neurofibroma tumor burdwith durable results after drug discontinuation in a mouse modof neurofibromatosis type 1. Pediatr Blood Cancer. 2020 Aug;67:e28372. doi: 10.1002/pbc.28372. Epub 2020 May 27. PMCIPMC32459399

Brosseau JP, Liao CP, Le LQ. Translating current basresearch into future therapies for neurofibromatosis type 1. J Cancer. 2020 Jul;123(2):178-186. doi: 10.10s41416-020-0903-x. Epub 2020 May 22. PMCID: PMC7374719

Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb Fisher MJ, Weiss B, Kim A, Bornhorst M, Shah AC, Martin Roderick MC, Pichard DC, Carbonell A, Paul SM, Therrien Kapustina O, Heisey K, Clapp DW, Zhang C, Peer CJ, Figg WSmith M, Glod J, Blakeley JO, Steinberg SM, Venzon DJ, Doyle LWidemann BC. Selumetinib in Children with Inoperable PlexifoNeurofibromas. N Engl J Med. 2020 Apr 9;382(15):1430-1442. do10.1056/NEJMoa1912735. Epub 2020 Mar 18. PMCID: PMC7305659.

Fisher MJ, Shih CS, Rhodes SD, Armstrong AE, WoltePL, Dombi E, Zhang C, Angus SP, Johnson GL, Packer RJ, Allen JUllrich NJ, Goldman S, Gutmann DH, Plotkin SR, Rosser Robertson KA, Widemann BC, Smith AE, Bessler WK, He Y, Park SMund JA, Jiang L, Bijangi-Vishehsaraei K, Robinson CT, CuttGR, Korf BR; Neurofibromatosis Clinical Trials ConsortiuBlakeley JO, Clapp DW. Cabozantinib for neurofibromatosis ty1-related plexiform neurofibromas: a phase 2 trial. Nat Med 20Jan;27(1):165-173. doi: 10.1038/s41591-020-01193-6. Epub 20Jan 13. PMID: 3344201

Stieglitz E, Mazor T, Olshen AB, Geng H, Gelston LAkutagawa J, Lipka DB, Plass C, Flotho C, Chehab FF, Braun BCostello JF, Loh ML. Genome-wide DNA methylation is predictiof outcome in juvenile myelomonocytic leukemia. Nat Commun. 20Dec 19;8(1):2127. doi: 10.1038/s41467-017-02178-9. PMCIPMC5736624.

Schönung M, Meyer J, Nöllke P, Olshen AB, Hartmann Murakami N, Wakamatsu M, Okuno Y, Plass C, Loh ML, Niemeyer CMuramatsu H, Flotho C, Stieglitz E, Lipka DB. InternationConsensus Definition of DNA Methylation Subgroups in JuveniMyelomonocytic Leukemia. Clin Cancer Res. 2021 Jan 1;27:158-168. doi: 10.1158/1078-0432.CCR-20-3184. Epub 2020 Nov PMCID: PMC7785676.

Wong JC, Perez-Mancera PA, Huang TQ, Kim J, Grego-BesJ, del pilar Alzamora M, Kogan SC, Sharir A, Keefe SH, MoralC, Schanze D, Zenker M, Sheppard D, Klein OD, Tuveson DA, BraBS*, Shannon K*. KrasP34R and KrasT58I mutations induce distinRASopathy phenotypes in mice. JCI Insight Sep 29:140495. doi: 1172/jci.insight.140495. PMCID: PMC7710308.

Chao AK1, Meyer JA1, Lee AG1, Hecht A1, Tarver T2, VZiffle J3, Koegel AK1, Golden C4, Braun BS1,5, Sweet-Cordero E5, Smith CC2,5, Dvorak CC1,5, Loh ML1,5, Stieglitz E6,7. Fusidriven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenidentified by RNA sequencing. Leukemia. 2019 Sep 12. doi: 1038/s41375-019-0549-y. [Epub ahead of print]. PMCID: PMC69957

Burks CA, Rhodes, RD, Besser WK, Chen S, Smith Gehlhausen JR, Hawley ET, Jiang L, Li X, Yuan J, Lu Q, JacobsM, Sandusky GE, Jones DR, Clapp DW, Blakeley JO. KetotifModulates Mast Cell Chemotaxis to Kit-Ligand, but Does NImpact Mast Cell Numbers, Degranulation, or Tumor Behavior Neurofibromas of Nf1-Deficient Mice. Molecular CancTherapeutics. Mol Cancer Ther. 2019 Sep 16. pii: molcanther.012019. doi: 10.1158/1535-7163.MCT-19-0123. [Epub ahead of print]. – PMCID: PMC7482139.

Brosseau JP, Le LQ. Heterozygous Tumor SuppressMicroenvironment in Cancer Development. Trends Cancer. 2019 Sep; 5(9):541-546. doi: 10.1016/j.trecan.2019.07.004. Epub 2019 A15. Review. PMCID: PMC6724550.

Hecht A, Meyer J, Chehab FF, White KL, Magruder Dvorak CC, Loh ML, Stieglitz E. Molecular assessment pretransplant chemotherapy in the treatment of juvenimyelomonocytic leukemia. Pediatr Blood Cancer. 2019 Jul :e27948. doi: 10.1002/pbc.27948. [Epub ahead of print]. PMC6754267.

Ferner RE, Bakker A, Elgersma Y, Evans DGR, GiovanniM, Legius E, Lloyd A, Messiaen LM, Plotkin S, Reilly KSchindeler A, Smith MJ, Ullrich NJ, Widemann B, Sherman LS. Frprocess to progress-2017 International Conference Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis. J Med Genet A. 2019;179(6):1098-1106. doi: 10.1002/ajmg.a.6111Epub 2019 Mar 25. PMCID: PMC6488427.

Brosseau, J.P., Liao, C.P., Wang, Y., Ramani, VVandergriff, T., Lee, M., Patel, A., Ariizumi, K., and Le, L.(2018). NF1 heterozygosity fosters de novo tumorigenesis bimpairs malignant transformation. Nature Communications. 9:50DOI: 10.1038/s41467-018-07452-y. PMCID: PMC6258697.

Dvorak CC, Satwani P, Stieglitz E, Cairo MS, Dang Pei Q, Gao Y, Wall D, Mazor T, Olshen AB, Parker JS, Kahwash Hirsch B, Raimondi S, Patel N, Skeens M, Cooper T, Mehta PGrupp SA, Loh ML. Disease burden and conditioning regimens ASCT1221, a randomized phase II trial in children with juvenimyelomonocytic leukemia: A Children's Oncology Group studPediatr Blood Cancer. 2018 Jul;65(7):e27034. doi: 10.1002/p27034. Epub 2018 Mar 12. PMCID: PMC5980696.

Liao, C.P., Booker, R.C., Brosseau, J.P., Chen, ZMo, J., Tchegnon, E., Wang, Y., Clapp, D.W., Le, L.Q. (2018). Contributions of inflammation and tumor microenvironment neurofibroma tumorigenesis. Journal of Clinical Investigati(JCI). PMCID: PMC6025974

Yoshimi A, Balasis ME, Vedder A, Feldman K, Ma Y, ZhaH, Lee SC, Letson C, Niyongere S, Lu SX, Ball M, Taylor J, ZhaQ, Zhao Y, Youssef S, Chung YR, Zhang XJ, Durham BH, Yang List AF, Loh ML, Klimek V, Berger MF, Stieglitz E, Padron Abdel-Wahab O. Robust patient-derived xenografts of MDS/Moverlap syndromes capture the unique characteristics of CMML aJMML. Blood. 2017 Jul 27;130(4):397-407. doi: 10.11blood-2017-01-763219. Epub 2017 Jun 2. PMCID: PMC5533204.

Liao, C.P., Booker, R.C., Morrison, S.J., Le, L.(2017). Identification of hair shaft progenitors that createniche for hair pigmentation. Genes & Development. 31(8744-756. PMCID: PMC5435888.

Ferguson MJ, Rhodes SD, Jiang L, Li X, Yuan J, Yang Zhang S, Vakili ST, Territo P, Hutchins G, Yang FC, Ingram DClapp DW, Chen S. Preclinical Evidence for the Use of SunitinMalate in the Treatment of Plexiform Neurofibromas. PediaBlood Cancer. 2016;63(2):206-13. Epub 2015/09/17. doi: 10.10pbc.25763. PMCID: PMC4862309.

Rhodes SD, He Y, Smith A, Jiang L, Lu Q, Mund J, Li Bessler W, Qian S, Dyer W, Sandusky GE, Horvai AE, Armstrong AClapp DW. Cdkn2a (Arf) loss drives NF1-associated atypicneurofibroma and malignant transformation. Hum Mol Genet. 20Aug 15;28(16):2752-2762. doi: 10.1093/hmg/ddz095. PMCIPMC6687955.